ATAI Quote, Financials, Valuation and Earnings

Innoviva, Inc. has a net margin of -8157.28% compared to Atai Beckley, Inc.'s net margin of 80.81%. Atai Beckley, Inc.'s return on equity of -91.85% beat Innoviva, Inc.'s return on equity of 32.01%.

Atai Beckley, Inc. has a consensus price target of $12.45, signalling upside risk potential of 243.1%. On the other hand Innoviva, Inc. has an analysts' consensus of $33.20 which suggests that it could grow by 44.6%. Given that Atai Beckley, Inc. has higher upside potential than Innoviva, Inc., analysts believe Atai Beckley, Inc. is more attractive than Innoviva, Inc..

Atai Beckley, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Innoviva, Inc. has a beta of 0.437, suggesting its less volatile than the S&P 500 by 56.321%.

Atai Beckley, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innoviva, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atai Beckley, Inc. pays -- of its earnings as a dividend. Innoviva, Inc. pays out -- of its earnings as a dividend.

Atai Beckley, Inc. quarterly revenues are $749K, which are smaller than Innoviva, Inc. quarterly revenues of $118M. Atai Beckley, Inc.'s net income of -$61.1M is lower than Innoviva, Inc.'s net income of $164.2M. Notably, Atai Beckley, Inc.'s price-to-earnings ratio is -- while Innoviva, Inc.'s PE ratio is 7.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atai Beckley, Inc. is 222.52x versus 4.29x for Innoviva, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -8157.28% compared to Atai Beckley, Inc.'s net margin of 20.83%. Atai Beckley, Inc.'s return on equity of -91.85% beat Johnson & Johnson's return on equity of 34.46%.

Atai Beckley, Inc. has a consensus price target of $12.45, signalling upside risk potential of 243.1%. On the other hand Johnson & Johnson has an analysts' consensus of $232.50 which suggests that it could fall by -6.41%. Given that Atai Beckley, Inc. has higher upside potential than Johnson & Johnson, analysts believe Atai Beckley, Inc. is more attractive than Johnson & Johnson.

Atai Beckley, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.350, suggesting its less volatile than the S&P 500 by 64.977%.

Atai Beckley, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.09% to investors and pays a quarterly dividend of $1.30 per share. Atai Beckley, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Atai Beckley, Inc. quarterly revenues are $749K, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Atai Beckley, Inc.'s net income of -$61.1M is lower than Johnson & Johnson's net income of $5.1B. Notably, Atai Beckley, Inc.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 22.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atai Beckley, Inc. is 222.52x versus 6.40x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -8157.28% compared to Atai Beckley, Inc.'s net margin of 21.74%. Atai Beckley, Inc.'s return on equity of -91.85% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Atai Beckley, Inc. has a consensus price target of $12.45, signalling upside risk potential of 243.1%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $869.96 which suggests that it could grow by 11.3%. Given that Atai Beckley, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Atai Beckley, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Atai Beckley, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.232%.

Atai Beckley, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.46% to investors and pays a quarterly dividend of $0.94 per share. Atai Beckley, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Atai Beckley, Inc. quarterly revenues are $749K, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Atai Beckley, Inc.'s net income of -$61.1M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Atai Beckley, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atai Beckley, Inc. is 222.52x versus 5.92x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.